201 related articles for article (PubMed ID: 269449)
1. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA
Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449
[TBL] [Abstract][Full Text] [Related]
2. A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid. Two selective thromboxane synthetase inhibitors.
Fitzpatrick FA; Gorman RR
Biochim Biophys Acta; 1978 Mar; 539(2):162-72. PubMed ID: 629996
[TBL] [Abstract][Full Text] [Related]
3. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
4. Thromboxane synthetase inhibitors as pharmacological tools: differential biochemical and biological effects on platelet suspensions.
Needleman P; Bryan B; Wyche A; Bronson SD; Eakins K; Ferrendelli JA; Minkes M
Prostaglandins; 1977 Nov; 14(5):897-907. PubMed ID: 594391
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
[TBL] [Abstract][Full Text] [Related]
6. 9,11-Iminoepoxyprosta-5,13-dienoic acid is a selective thromboxane A2 synthetase inhibitor.
Fitzpatrick F; Gorman R; Bundy G; Honohan T; McGuire J; Sun F
Biochim Biophys Acta; 1979 May; 573(2):238-44. PubMed ID: 375987
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 9,11-azo-13-oxa-15-hydroxyprostanoic acid, a potent inhibitor of platelet aggregation.
Kam ST; Portoghese PS; Gerrard JM; Dunham EW
J Med Chem; 1979 Nov; 22(11):1402-8. PubMed ID: 533888
[TBL] [Abstract][Full Text] [Related]
9. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
Bertele V; De Gaetano G
Eur J Pharmacol; 1982 Dec; 85(3-4):331-3. PubMed ID: 6295787
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
Gorman RR
Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
[No Abstract] [Full Text] [Related]
12. Inhibition of thromboxane synthesis and platelet aggregation by pyridine and its derivatives.
Tai HH; Lee N; Tai CL
Adv Prostaglandin Thromboxane Res; 1980; 6():447-52. PubMed ID: 7189951
[TBL] [Abstract][Full Text] [Related]
13. Effects of 2-indolecarbohydrazides on thromboxane synthetase activity and on in vitro and ex vivo blood platelet aggregation. New selective inhibitors.
Monge A; Erro A; Parrado P; Font M; Aldana I; Rocha E; Fernandez-Alvarez E
Arzneimittelforschung; 1986 Aug; 36(8):1184-6. PubMed ID: 3096343
[TBL] [Abstract][Full Text] [Related]
14. 9, 11-Azo-12-oxa-15-hydroxyprostanoic acid: a potent thromboxane synthetase inhibitor and a PGH2/TxA2 receptor antagonist.
Kam ST; Portoghese PS
Prostaglandins Med; 1979 Nov; 3(5):279-90. PubMed ID: 233035
[TBL] [Abstract][Full Text] [Related]
15. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence.
Miller OV; Ayer DE; Gorman RR
Biochim Biophys Acta; 1982 Jun; 711(3):445-51. PubMed ID: 6285985
[TBL] [Abstract][Full Text] [Related]
16. 9 alpha-homo-9,11-epoxy-5,13-prostadienoic acid analogues: specific stable agonist (SQ 26, 538) and antagonist (SQ 26, 536) of the human platelet thromboxane receptor.
Harris DN; Phillips MB; Michel IM; Goldenberg HJ; Heikes JE; Sprague PW; Antonaccio MJ
Prostaglandins; 1981 Aug; 22(2):295-307. PubMed ID: 6270744
[TBL] [Abstract][Full Text] [Related]
17. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
Kuzuya T; Hoshida S; Yamagishi M; Ohmori M; Inoue M; Kamada T; Tada M
Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
19. Kinetic studies on the conversion of prostaglandin endoperoxide PGH2 by thromboxane synthase.
Anderson MW; Crutchley DJ; Tainer BE; Eling TE
Prostaglandins; 1978 Oct; 16(4):563-70. PubMed ID: 725086
[TBL] [Abstract][Full Text] [Related]
20. Platelet rich plasma transforms exogenous prostaglandin endoperoxide H2 into thromboxane A2.
Fitzpatrick FA; Gorman RR
Prostaglandins; 1977 Nov; 14(5):881-9. PubMed ID: 594390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
